The anxiolytic effects of flesinoxan, a 5-HT(1A) receptor agonist, are not related to its neuroendocrine effects

Publication date

1995-01-14

Authors

Groenink, LucianneORCID 0000-0002-4971-7796ISNI 0000000394881736
Van der Gugten, J.ISNI 0000000394061631
Verdouw, Monika PORCID 0000-0002-5071-5907ISNI 000000039406543X
Maes, R.A.A.
Olivier, BerendISNI 0000000116225595

Editors

Advisors

Supervisors

Document Type

Article
Open Access logo

License

taverne

Abstract

The effects of flesinoxan, a selective 5-HT(1A) receptor agonist, were studied under basal non-stress conditions and in the shock-probe burying paradigm. Flesinoxan (1 and 3 mg/kg s.c.) significantly reduced burying and freezing behaviour, indicating clear anxiolytic properties. Under non-stress conditions, injection of 3 mg/kg flesinoxan significantly enhanced plasma corticosterone and glucose levels, whereas prolactin secretion was significantly enhanced after both 1 mg/kg and 3 mg/kg flesinoxan. Flesinoxan (1 and 3 mg/kg) did not suppress shock-probe stress-induced rises in plasma corticosterone and glucose levels. The enhanced plasma prolactin levels induced by flesinoxan were not further affected by shock-probe exposure. Our data show that the anxiolytic effects of flesinoxan in the shock-probe burying paradigm are not related to increases in plasma corticosterone and glucose levels.

Keywords

5-HT(1A) receptor, Anxiety, Corticosterone, Defensive burying, Flesinoxan, Glucose, Prolactin, anxiolytic agent, corticosterone, flesinoxan, glucose, prolactin, serotonin 1A agonist, serotonin 1A receptor, serotonin agonist, animal experiment, animal model, article, controlled study, corticosterone blood level, defensive behavior, electric shock, glucose blood level, male, neuroendocrine system, nonhuman, priority journal, prolactin blood level, prolactin release, rat, stress, subcutaneous drug administration, tranquilizing activity, Taverne

Citation

Groenink, L, Van der Gugten, J, Verdouw, P M, Maes, R A A & Olivier, B 1995, 'The anxiolytic effects of flesinoxan, a 5-HT(1A) receptor agonist, are not related to its neuroendocrine effects', European Journal of Pharmacology, vol. 280, no. 2, pp. 185-193. https://doi.org/10.1016/0014-2999(95)00209-4